Navigation Links
Idenix Reports Advancement of HCV Development Pipeline
Date:1/9/2012

CAMBRIDGE, Mass., Jan. 9, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the advancement of its hepatitis C virus (HCV) development pipeline.

IDX719: NS5A Program
Idenix announced today the initiation of a phase I clinical trial of the Company's NS5A inhibitor, IDX719. The first part of the study will evaluate safety, pharmacokinetics and food effect of IDX719 in 48 healthy volunteers. A subsequent part of the study will evaluate three days of IDX719 treatment in treatment-naïve genotype 1 HCV-infected patients and is expected to begin in the second quarter of 2012. Preclinical studies have shown that IDX719 has potent, pan-genotypic activity in vitro with the potential for once-daily dosing.

IDX19368 and IDX19370: Nucleotide Prodrug Program
Further, the Company has selected two additional nucleotide inhibitors, IDX19368 and IDX19370, as potential clinical candidates. The Company anticipates Investigational New Drug (IND) filings in mid-2012.

"Over the past year, Idenix has made significant progress in both our core nucleotide and NS5A programs," commented Ron Renaud, President and Chief Executive Officer of Idenix. "The preclinical profile of IDX719 is very competitive, and we are leveraging the Company's significant nucleotide chemistry expertise to discover novel nucleotides with promising properties as well as continuing to strengthen our IP position. We are excited about the potential of our novel antiviral compounds in the evolving HCV field in the coming year."

2011 Year-end Cash Balance
Idenix today reported that it ended 2011 with approximately $118.3 million of cash and cash equivalents. The Company's 2011 financial results have not yet been
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
2. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
3. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
4. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
5. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
6. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
7. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
8. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
9. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
10. Idenix Pharmaceuticals Reports First Quarter Financial Results
11. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Egenix, Inc. is pleased to announce that ... the Board, to succeed Donald Fresne ; Mr. Fresne ... as a member of the Board.  In recognition of the ... company over almost twenty years, the Board designated Mr. Fresne ... has established a Search Committee to find a suitable replacement ...
(Date:12/17/2014)... Based on the revenues gained from surgical imaging ... by four major players contributing to approximately 74% ... GE Healthcare (U.K.), Siemens AG (Germany), Philips (Netherlands), ... Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The leading ... its strong product portfolio, which includes its flagship ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Once more, ... provide a larger packaged waste water treatment plant to ... Abdullah Economic City (KAEC). Two years ago Bioshaft successfully ... Gate Development, serving two residential towers with an occupancy ... over a quarter million gallons per day and was ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... 28 Today the Swiss,pharmaceutical group Helsinn announced ... Inc. with headquarters in,Bridgewater, New Jersey, for an ... establishment of a US-based R&D and commercial operation ... strategic goals. "We are,thrilled at this very important ...
... Jan. 28 BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) ... host a conference call and webcast on,Wednesday, February 18, at ... year 2008 financial results. , , U.S. ... Dial-in Number: 617.213.8835, Participant Code: 35749059, ...
... Cytopia Ltd (ASX: CYT) has joined with other Progen Pharmaceuticals ... elect a new board, pursue a merger and enable the first ... Progen shareholders include: , , ... so the opportunity of having their shares bought back for $1.10 ...
Cached Biology Technology:Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc. 2Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc. 3BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET) 2Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders 2Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders 3Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders 4Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders 5
(Date:11/18/2014)... 2014  The Secure Identity & Biometrics Association ... announce the formation of The Airport Entry and ... Identity and Biometric Entry and Exit Solutions Framework ... support from BORDERPOL, the international non-profit organization that ... expertise regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
(Date:11/15/2014)... 2014  While we may still be a few years ... "Star Trek" to gain instant access to all that ailed ... smartphones and tablets for monitoring and measuring our health are ... may seem a tad Orwellian to some, but a new ... these technological opportunities into their healthcare regime. These ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... the January and February issues of the Journal ... and colleagues have extensively characterized a previously unidentified process ... membrane can be reversibly endocytosed. This massive endocytosis ... types with a range of different experimental manipulations, including ...
... has been shown to significantly reduce the symptoms of premenstrual ... Reproductive Health tested the tablets by carrying out ... Filho worked with a team of researchers from the Federal ... "The administration of 1 or 2 grams of essential fatty ...
... , HOUSTON A small slice of RNA inhibits prostate ... prostate cancer stem cells. A research team led by scientists ... today in an advance online publication at Nature Medicine ... microRNA expression pattern in prostate cancer stem cells and also ...
Cached Biology News:MicroRNA suppresses prostate cancer stem cells and metastasis 2
... PCR Spots, Oligo Spots and complementary RNA ... microarray experiments. Use for glass array printing ... for reverse transcription, cDNA labeling, hybridization stringency ... Control PCR Spots and Oligo Spots, ...
Kit for Detection of Mitochondrial Membrane Potential...
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
MOUSE ANTI HUMAN C-MYC aa171-188...
Biology Products: